|
Neonatal Intensive Care Drug Manual
|
| bet | 210/654 | | Sana | 03.01.2022 | | Hajmi | 1,5 Mb. | | #14803 |
Drug interactions
|
Use of any of the drugs prolonging QT interval (cisapride, amiodarone, clarithromycin, chloral hydrate, ciprofloxacin, erythromycin, octreotide, sodium phosphate, vasopressin, ketoconazole, fluconazole, hydrochlorothiazide, azithromycin, propranolol, digoxin, verapamil) with flecainide can lead to significant increase in QT interval.
|
Adverse reactions
|
Adults:
Common
Cardiovascular: Palpitations (6.1%); Gastrointestinal: Nausea (up to 10%); Neurological: Dizziness (18.9% to 30%), Headache (4.5% to 9.6%); Ophthalmological: Blurred vision (10% to 38%), Photopsia (up to 30%); Respiratory: Dyspnoea (up to 10.3%); Other: Fatigue (7.7%).
Serious
Cardiac arrest, cardiac dysrhythmia, cardiogenic shock, disorder of pacing function, electrocardiogram abnormalities, heart block, heart failure (new onset or worsening [up to 25.7%]), prolonged QT interval, sinus node dysfunction (1% to less than 3% ), syncope (1% to less than 3% ), torsades de pointes, ventricular fibrillation, ventricular tachycardia.
Children:
Dizziness, blurred vision and headache have been reported in children.
|
Compatibility
|
5% glucose
|
Incompatibility
|
Incompatible with alkaline and chloride-containing solutions.
|
Stability
|
Diluted solution stable for 24 hours at 25oC.
Oral suspension compounded by Pharmacy stable for up to 60 days.
|
Storage
|
|
Excipients
|
Silicified microcrystalline cellulose, croscarmellose sodium, maize starch, magnesium stearate.
|
|
|
| |
